Xue‐Wu Wei

593 total citations · 1 hit paper
13 papers, 287 citations indexed

About

Xue‐Wu Wei is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Xue‐Wu Wei has authored 13 papers receiving a total of 287 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in Xue‐Wu Wei's work include Lung Cancer Treatments and Mutations (9 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Cancer Genomics and Diagnostics (4 papers). Xue‐Wu Wei is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Cancer Genomics and Diagnostics (4 papers). Xue‐Wu Wei collaborates with scholars based in China, India and Canada. Xue‐Wu Wei's co-authors include Qing Zhou, Yi‐Long Wu, Zhihong Chen, Xiaorong Yang, Wen‐Zhao Zhong, Fen Wang, Chong‐Rui Xu, Bo Zhang, Weidong Chen and Lei Yang and has published in prestigious journals such as Nature Reviews Clinical Oncology, Journal of Gastroenterology and Hepatology and Journal for ImmunoTherapy of Cancer.

In The Last Decade

Xue‐Wu Wei

13 papers receiving 284 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma

2022 120 citations Lei Yang, Song Dong et al. Journal for ImmunoTherapy of Cancer profile →

Peers

Countries citing papers authored by Xue‐Wu Wei

Since Specialization

Citations

This map shows the geographic impact of Xue‐Wu Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xue‐Wu Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xue‐Wu Wei more than expected).

Fields of papers citing papers by Xue‐Wu Wei

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xue‐Wu Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xue‐Wu Wei. The network helps show where Xue‐Wu Wei may publish in the future.

Co-authorship network of co-authors of Xue‐Wu Wei

This figure shows the co-authorship network connecting the top 25 collaborators of Xue‐Wu Wei. A scholar is included among the top collaborators of Xue‐Wu Wei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xue‐Wu Wei. Xue‐Wu Wei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer 2025 ·Nature Reviews Clinical Oncology ·(unknown), (unknown), Ji Chen, (unknown), Mei-Mei Zheng, Wu Lv, Chang Lu, Xue‐Wu Wei, Dongqing Cai, Zhi Guo, (unknown), Shichao Lv, Yu Deng, Zhihong Chen, Chong‐Rui Xu, Qing Zhou	3
2	Redox ^high phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinoma 2024 ·OncoImmunology ·Xue‐Wu Wei, (unknown), (unknown), Xue Fan, Chong‐Rui Xu, Zhihong Chen, Fen Wang, Xiaorong Yang, Jia‐Yi Deng, (unknown), (unknown), (unknown), (unknown), (unknown), Wen‐Zhao Zhong, Jin‐Ji Yang, Xu‐Chao Zhang, (unknown), Yi‐Long Wu, Qing Zhou	11
3	Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer 2023 ·Journal for ImmunoTherapy of Cancer ·Jia‐Yi Deng, (unknown), Lingling Yang, Zhihong Chen, (unknown), Xiaorong Yang, Hong‐Hong Yan, Xue‐Wu Wei, (unknown), Jian Su, Wen‐Zhao Zhong, Chong‐Rui Xu, Yi‐Long Wu, Qing Zhou	23
4	Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma breakdown → 2022 ·Journal for ImmunoTherapy of Cancer ·Lei Yang, (unknown), Song Dong, Xue‐Wu Wei, Zhihong Chen, Bo Zhang, Weidong Chen, Xiaorong Yang, Fen Wang, (unknown), Wen‐Zhao Zhong, Yi‐Long Wu, Qing Zhou	120
5	Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non–Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705) 2022 ·Clinical Lung Cancer ·Si‐Yang Maggie Liu, Hong‐Hong Yan, Xue‐Wu Wei, Chang Lu, Xiaorong Dong, Yingying Du, Jiuwei Cui, Yuan Chen, Rui Ma, Buhai Wang, Zhen Zhou, Shundong Cang, Jin‐Ji Yang, Hai‐Yan Tu, Xuchao Zhang, Wen‐Zhao Zhong, Qing Zhou, Yi‐Long Wu	4
6	Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes 2022 ·Journal of Cancer Research and Clinical Oncology ·Chang Lu, Xue‐Wu Wei, Yichen Zhang, Zhihong Chen, Chong‐Rui Xu, Ming-Ying Zheng, Jin‐Ji Yang, Xu‐Chao Zhang, Qing Zhou	3
7	Characteristics of and Treatment Strategies for Advanced EGFR-Mutant NSCLC With Concomitant BRAF Variations 2022 ·JTO Clinical and Research Reports ·Xue‐Wu Wei, Jia‐Yi Deng, Chong‐Rui Xu, Zhihong Chen, Dongqin Zhu, Qian Wu, Xu‐Chao Zhang, Yi‐Long Wu, Qing Zhou	4
8	Organ-specific efficacy in advanced non-small cell lung cancer patients treated with first-line single-agent immune checkpoint inhibitors 2022 ·Chinese Medical Journal ·Jia‐Yi Deng, Ming Gao, (unknown), Chong‐Rui Xu, Hong‐Hong Yan, (unknown), (unknown), Xiaorong Yang, Xue‐Wu Wei, Qing Zhou	13
9	Mutational landscape and characteristics of ERBB2 in non‐small cell lung cancer 2020 ·Thoracic Cancer ·Xue‐Wu Wei, Xin Gao, Xu‐Chao Zhang, Jin‐Ji Yang, Zhihong Chen, Yi‐Long Wu, Qing Zhou	35
10	Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer 2020 ·Journal of Thoracic Disease ·Xin Gao, Xue‐Wu Wei, Ming-Ying Zheng, Zhihong Chen, Xu‐Chao Zhang, Wen‐Zhao Zhong, Jin‐Ji Yang, Yi‐Long Wu, Qing Zhou	6
11	Benign disease prone to be misdiagnosed as malignant pulmonary nodules: Minute meningothelioid nodules 2019 ·Thoracic Cancer ·Xiaoxiao Peng, Li‐Xu Yan, Chao Liu, (unknown), Wenfeng Li, Xing Gao, Xue‐Wu Wei, Qing Zhou	11
12	EGFR mutations in early‐stage and advanced‐stage lung adenocarcinoma: Analysis based on large‐scale data from China 2018 ·Thoracic Cancer ·(unknown), Chong‐Rui Xu, Mingfeng Zhang, Xiaoxiao Peng, Xue‐Wu Wei, Xing Gao, Hong‐Hong Yan, Qing Zhou	42
13	Characterization of fibrosis changes in chronic hepatitis C patients after virological cure: A systematic review with meta‐analysis 2016 ·Journal of Gastroenterology and Hepatology ·Zhi-Peng Liu, Xue‐Wu Wei, Ting Chen, (unknown), Haiyan Liu, Yan Wang	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact